CANIGEN DHPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION FOR DOGS

Authorised

- Canine adenovirus 2, strain Manhattan, Live
- Canine parainfluenza virus, strain Manhattan, Live
- Canine parvovirus, strain Cornell 780916, Live
- Canine distemper virus, strain Lederle, Live

Product identification

Medicine name:
CANIGEN DHPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION FOR DOGS
Canigen CHPPi lyofilisat og væske til injeksjonsvæske, suspensjon til hund

Active substance:
Canine adenovirus 2, strain Manhattan, Live

Canine parainfluenza virus, strain Manhattan, Live

Canine parvovirus, strain Cornell 780916, Live

Canine distemper virus, strain Lederle, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Canine adenovirus 2, strain Manhattan, Live
10000.00 50% tissue culture infectious dose / 1.00 unit(s)

Canine parainfluenza virus, strain Manhattan, Live
100000.00 50% tissue culture infectious dose / 1.00 unit(s)

Canine parvovirus, strain Cornell 780916, Live
100000.00 50% tissue culture infectious dose / 1.00 unit(s)

Canine distemper virus, strain Lederle, Live
1000.00 50% tissue culture infectious dose / 1.00 unit(s)

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AD04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Norway

Available in:

Norway

Package description:

Cardboard box of 1 vial lyophilisate and 1 vial solvent

Plastic box of 100 vials lyophilisate and 100 vials solvent
Plastic box of 50 vials lyophilisate and 50 vials solvent
Plastic box of 25 vials lyophilisate and 25 vials solvent
Plastic box of 10 vials lyophilisate and 10 vials solvent
Plastic box of 5 vials lyophilisate and 5 vials solvent
Plastic box of 1 vial lyophilisate and 1 vial solvent
Cardboard box of 100 vials lyophilisate and 100 vials solvent
Cardboard box of 50 vials lyophilisate and 50 vials solvent
Cardboard box of 25 vials lyophilisate and 25 vials solvent
Cardboard boxof 10 vials lyophilisate and 10 vials solvent
Cardboard box of 5 vials lyophilisate and 5 vials solvent

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Virbac

Marketing authorisation date:
8/09/2016

Manufacturing sites for batch release:
Virbac

Responsible authority:
Norwegian Medical Products Agency

Authorisation number:
15-10770

Date of authorisation status change:
21/03/2021

Reference member state:
France

Procedure number:
FR/V/0297/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Source URL: *https://medicines.health.europa.eu/veterinary/600000032592*